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Abstract
Background: Schizophrenia (SZ) is a heritable, complex mental disorder. We have seen limited success in finding causal
genes for schizophrenia from numerous conventional studies. Protein interaction network and pathway-based analysis may
provide us an alternative and effective approach to investigating the molecular mechanisms of schizophrenia.
Methodology/Principal Findings: We selected a list of schizophrenia candidate genes (SZGenes) using a multi-dimensional
evidence-based approach. The global network properties of proteins encoded by these SZGenes were explored in the
context of the human protein interactome while local network properties were investigated by comparing SZ-specific and
cancer-specific networks that were extracted from the human interactome. Relative to cancer genes, we observed that
SZGenes tend to have an intermediate degree and an intermediate efficiency on a perturbation spreading throughout the
human interactome. This suggested that schizophrenia might have different pathological mechanisms from cancer even
though both are complex diseases. We conducted pathway analysis using Ingenuity System and constructed the first
schizophrenia molecular network (SMN) based on protein interaction networks, pathways and literature survey. We
identified 24 pathways overrepresented in SZGenes and examined their interactions and crosstalk. We observed that these
pathways were related to neurodevelopment, immune system, and retinoic X receptor (RXR). Our examination of SMN
revealed that schizophrenia is a dynamic process caused by dysregulation of the multiple pathways. Finally, we applied the
network/pathway approach to identify novel candidate genes, some of which could be verified by experiments.
Conclusions/Significance: This study provides the first comprehensive review of the network and pathway characteristics of
schizophrenia candidate genes. Our preliminary results suggest that this systems biology approach might prove promising
for selection of candidate genes for complex diseases. Our findings have important implications for the molecular
mechanisms for schizophrenia and, potentially, other psychiatric disorders.
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Introduction
Schizophrenia (SZ) is a severe mental disorder affecting ,1% of
the population [1]. Family, twin, and adoption studies strongly
support that genetic factors play an important role in the etiology of
schizophrenia. Recently, numerous genetic studies, including
linkage scans and their meta-analyses, candidate gene association
analyses, gene expression and genome-wide association studies
(GWAS), have identified specific genes/markers and chromosomal
regions for the disease [2,3,4,5]. Though these studies present a low
replication, more evidence supports that the etiology of schizophre-
nia involves, rather than single genes/loci with large effect, many
genes, each of which contributes a small risk, interacting with each
other or with environmental risk factors to cause schizophrenia [3].
In this study we hypothesize that these small effects are organized in
networks/pathways and these schizophrenia disease networks/
pathways have important features that are distinct from those seen
in other diseases such as cancer or Mendelian genetic diseases.
It is increasingly possible to investigate biological networks/
pathways of a complex disease at the systems level because of the
rapid accumulation of genetic and biological information in the past
decade. Recent studies reveal striking correlations between the
functions of gene products or gene networks and the features of the
diseases they cause [6,7]. The correlation between the attributes of
disease genes is more extensive and stronger than previously thought.
This was revealed in an analysis of Gene Ontology (GO) terms and a
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gene expression pattern of .1,600 genes causing different types of
diseases [8]. Further, Goh et al [9] found that the majority of disease
genes are nonessential and do not encode hub proteins (highly
connected proteins) in protein networks. This pattern was different
from that previously thought and that observed in cancer genes.
Except for only a few diseases such as cancer [10], there has been no
systematic investigation of the network properties of a complex
disease by examining the whole human interactome. Specifically, we
have been unable to find such a detailed examination of features for
schizophrenia associated genes.
In this study, we explored network characteristics of 160
schizophrenia candidate genes (SZGenes) that were prioritized by
a multi-dimensional evidence-based gene ranking approach [11].
Their global network characteristics and local network environment
indicate that SZGenes have their own network properties compared
to the cancer genes. We further identified schizophrenia enriched
pathways, explored their ability to interact with or influence each
other (crosstalk), and constructed the first version of a schizophrenia
molecular network (SMN). Finally, we applied our networks/
pathways analysis to identify novel candidate genes. Our prelim-
inary experimental verification suggests that this approach might be
promising. This study provides useful insights into the molecular
mechanisms of schizophrenia at the systems biology level.
Results
Global network properties of schizophrenia candidate
genes (SZGenes)
To date, no gene has been confirmed to be the cause of
schizophrenia. In this study, we used 160 SZGenes that were
prioritized based on a multi-dimensional evidence-based gene
ranking approach [11]. These genes were selected by integrative
evidence from linkage, association, gene expression and literature
search. Evaluations from several methods such as independent
GWAS P values, gene expression features, and GO annotations
suggest these genes are useful for follow up bioinformatics analysis
(Text S1, Table S1). For comparison, we compiled four other gene
sets: cancer genes, essential genes, neurodevelopment-related
genes (NeuroGenes) and non-disease, non-essential genes (NDE-
Genes) (see details in Text S1).
To explore the topological network properties of five gene sets, we
first reconstructed a human protein-protein interaction (PPI)
network (the human interactome, Text S1). In the human PPI
network, nodes represent the proteins encoded by genes and edges
(links) represent the interactions identified by experiments. Second-
ly, we mapped the proteins encoded by the five gene sets onto the
whole network, and then calculated the numbers of interactors
(namely, degree or connectivity) of nodes, and the shortest-path
distances (number of edges from one node to another). They are the
basic topological network measures, which provide insights into the
architecture of the nodes of interest (i.e., proteins encoded by
SZGenes) in the whole network (see Materials and Methods) [12].
Moderate connectivity (degree) of SZGenes. Figure 1
displays degree distribution and the average degree of the nodes in
each gene set. The average degree of SZGenes was 14.34, which
was significantly higher than that of NeuroGenes (10.88, Wilcoxon’s
test, P= 0.04) or that of NDEGenes (8.17, P= 8.261028) but
significantly lower than that of essential genes (18.39, P= 0.02) or
that of cancer genes (26.69, P= 6.361027). SZGenes had an
intermediate connectivity when compared to the four other gene
Figure 1. Degree distributions and average degrees (vertical lines) of five gene sets. The Y-axis represents the proportion of proteins
having a specific degree. The empirical P value in the inserted table indicates whether the observed average degree in a gene set is random from the
human interactome.
doi:10.1371/journal.pone.0011351.g001
Schizophrenia Network/Pathways
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sets, indicating that SZGenes often encode proteins that are
moderately connected, rather than highly connected in the human
interactome. This observation of higher degree in SZGenes and
cancer genes than in NeuroGenes or NDEGenes also supports a
recent report that disease genes tend to have higher degrees than
non-disease genes [10]. Moreover, proteins encoded by cancer
genes, essential genes and SZGenes had significantly more direct
interactions than randomly selected nodes (empirical P values are 0,
0, 0.02, respectively; here P= 0 means no randomly selected node
set had a higher average connectivity than the observed values of
cancer genes or essential genes), while proteins encoded by
NDEGenes had the opposite characteristic (empirical P= 1.00, all
randomly selected node sets had a higher average degree than the
observed values of NDEGenes).
The degree distributions of these five gene sets were strongly
right-skewed (Figure 1). Most nodes had low degree while only a
portion of nodes had a high degree, which were often defined as
‘‘hubs’’ in network analysis. There are multiple ways to define
hubs. Here, we applied the method in Yu et al [13] to define hubs.
We first plotted the degree distribution of all nodes in the human
interactome and then identified the point where the distribution
began to straighten out. The point corresponded to degree 13.
According to this cutoff, there were 2,165 nodes classified into
hubs, which accounted for 20.7% of all nodes in the interactome.
This proportion was consistent with the cutoff used in the yeast
interactome [14]. The proportion of hub proteins was 29.0%
among SZGenes, which was smaller than that of cancer genes
(49.4%) or essential genes (38.1%) but larger than that of
NeuroGenes (23.9%) or NDEGenes (16.6%). Figure S1 summa-
rizes the detailed distributions of proteins encoded by these gene
sets by a degree interval of 3. Among the five gene sets, the
proportion of SZGenes was the highest for degree intervals 4–6
and 7–9. For degree intervals 10–12 and 13–17, the proportion of
SZGenes was slightly smaller than that of cancer genes and similar
to that of essential genes. When we summarized degree intervals
4–17, the proportion of SZGenes was 50.0%, higher than any of
the other four gene sets (cancer genes: 47.5%, essential genes:
44.8%, NeuroGenes: 36.6%, and NDEGenes: 38.7%). Thus, the
average degree and degree distribution consistently indicate
intermediate connectivity of schizophrenia candidate genes.
Intermediate shortest-path distance of SZGenes. In a
network, shortest-path distance measures how many nodes need to
pass through from one node to another [12]. Considering the two
nodes might be our interest or not, we calculated shortest-path
distance in two ways: characteristic shortest-path distance and
global centrality. Characteristic shortest-path distance provides a
general view of the relationship between the nodes of interest and
all other nodes in the network while global centrality, which
calculates the shortest path distance between two nodes belonging
to the same gene set of interest, provides a measure of the general
view of the interest nodes in the whole network. The detailed
distributions and the average distance values of the five genes sets
are shown in Figure S2.
Similar to the degree measurement, SZGenes had an interme-
diate average characteristic shortest-path distance and global
centrality among the five gene sets (Figure S2). For example, the
average characteristic shortest-path distance of SZGenes was 3.88,
greater than that of cancer genes (3.63, Wilcoxon’s test,
P= 5.461027) or that of essential genes (3.76, P= 0.01) but less
than that of NDEGenes (3.98, P= 0.001) or NeuroGenes (3.93,
P= 0.09). The difference in global centrality between SZGenes and
the other four gene sets was even stronger than that in characteristic
shortest-path distances, e.g., the P values by the same test ranged
from ,2.2610216 to 2.761024. These comparisons indicate that
biological signal transferring from one SZGene to another SZGene
is faster than that between control genes (e.g. non-disease genes) but
slower than that between genes in the essential or cancer gene sets.
Therefore, these results imply that perturbation among SZGenes
spreads with intermediate efficiency throughout the human protein
interactome, which further suggests the damage of gene mutations
related to schizophrenia might be weaker than that of mutations in
some essential or cancer genes.
Schizophrenia-specific network
To explore the organization and the environment of the
proteins encoded by SZGenes, we extracted the schizophrenia
specific subnetwork (SZ-specific network) from the whole network
using SZGenes and the Steiner minimal tree algorithm [15]. For
comparison purpose, we extracted cancer-specific subnetwork
using cancer genes and the same algorithm. The cancer
subnetwork is shown in Figure S3.
Topological properties of the SZ-specific network. The
SZ-specific network had 233 nodes and 436 edges (links) while the
cancer-specific network had 324 nodes and 844 edges (Figure 2A,
Table S2). Among the 160 SZGenes, 135 (75.0%) were included in
the SZ-specific network, indicating a high coverage of SZGenes in
this subnetwork. However, the coverage was even higher in the
cancer-specific network, which included 265 of the 324 cancer
genes (94.6%). The average degree of the SZ-specific network
(3.74) was lower than that of cancer network (5.21), and
consistently, the average shortest-path distance of the SZ-specific
network (4.32) was greater than that of the cancer network (3.76)
(Table S2). These comparisons revealed that, relative to cancer
genes, SZGenes were weakly connected and had a lower efficiency
of navigability in the whole interactome. We further tested
randomness of the SZ-specific and cancer-specific networks using
the Erdos-Renyi model [16] (see Materials and Methods). The test
revealed that both gene sets formed non-random networks and
had a strong tendency to form clusters, as their shortest paths were
significantly different from that of random networks and clustering
coefficients were significantly higher than the corresponding
random networks (P values = 0, no any random network
outperformed the observed SZ- or cancer-specific network).
SZGenes distribute peripherally in SZ-specific
network. More than half of the genes (135/233 = 57.9%) in
the SZ-specific network were SZGenes and they formed 44 direct
edges (10.1% of the total 436 edges), indicating SZGenes might
approach each other directly or through other nodes to form a
small-world network. In a complex network, the ability of nodes to
communicate may reflect the network’s degree of robustness and
error tolerance [17]. Here, we used the k-clique clustering method
provided by CFinder software [18], which is a popular network
analysis method, to examine nodes’ distributions. This method
identifies the maximally complete subgraphs (k-cliques, in which
any two nodes have edges) in the networks and the communities,
in which two k-cliques share exactly k-1 nodes. We examined
cliques by five k values (k= 3, 4, 5, 6, 7). When k increased, the
number of nodes forming clusters decreased and, interestingly, the
proportion of SZGenes identified in the protein communities
decreased (Table S3). For example, 28.6% of SZGenes formed
communities when k= 3, but only 14.3% when k= 7. This result
indicates that SZGenes tend not to appear in the most tightly
connected communities. The opposite pattern was observed in
cancer genes, which was consistent with a previous report [10].
For k= 3, we found 70 cliques involving 63 proteins. These
cliques could form a large closely connected subnetwork
(Figure 2B). After we removed this subnetwork from the SZ-
specific network, connections among the remaining nodes became
Schizophrenia Network/Pathways
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11351
very loose and nearly corrupt (Figure 2C). Among these 63
proteins, 18 belong to SZGenes, which accounted for 13.3% of the
SZGenes in the SZ-specific network. By comparison, we observed
that 118 (44.5%) of the 265 cancer genes in the cancer-specific
network could form the clusters by 3-clique. The comparison
indicates that SZGenes tend to distribute peripherally in the
disease specific network rather than reside in the center of clusters,
a feature observed in cancer genes [10].
Schizophrenia enriched pathways
Pathways that are statistically enriched in a set of disease genes
may provide important cellular process information for our
Figure 2. Schizophrenia-specific network. SZGenes are labeled in red and non-SZGenes in blue. Node area corresponds to its degree in the
human interactome. Node shape indicates its cellular location: ellipse for cytoplasm, diamond for extracellular space, triangle for nucleus, square for
plasma membrane, and hexagon for unknown location. (A) The extracted schizophrenia-specific network from the human interactome. It has 233
nodes and 436 edges. (B) Network for the 63 nodes that could form clusters by CFinder. (C) Networks for the 170 nodes that could not form clusters
by CFinder.
doi:10.1371/journal.pone.0011351.g002
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understanding of the molecular pathology of the disease. We
examined schizophrenia enriched pathways (SZ-enriched path-
ways) using the Fisher’s exact test implemented in the Ingenuity
Pathway Analysis (IPA) (see Materials and Methods). Further, we
explored the interactions and crosstalk between SZ-enriched
pathways by taking advantage of both pathway and interaction
network data used in this study.
Twenty-four significantly enriched pathways for
SZGenes. We identified 24 pathways that were significantly
enriched for SZGenes (P value ,0.01) (Table S4). Among these 24
pathways, 9 (37.5%) were directly related to neurodevelopment.
This supports the commonly accepted notion of neuro-
developmental abnormalities in schizophrenia [19]. Interestingly,
a recent study identified 15 pathways that were overrepresented by
genes disrupted in schizophrenia cases versus controls, and these
pathways included 5 of our 9 neurodevelopment-related pathways
[20]. Four neurotransmitter-related pathways stood out at the top
of the list ranked by the significance level: glutamate receptor
signaling (ranked 1st), serotonin receptor signaling (2nd), GABA
receptor signaling (5th) and dopamine receptor signaling (7th).
Besides, two pathways, synaptic long-term depression and synaptic
long-term potentiation, were in the enriched pathway list. These
two pathways are important for synaptic plasticity development
and related to schizophrenia [21].
It was worth noting that, among the 24 pathways, 8 were
involved in or were related to the immune system. This supports
the autoimmune hypothesis of schizophrenia [22]. Recent studies
have been accumulating evidence of autoimmune-related genes
for the risk of schizophrenia [4,23]. For example, several inter-
leukin genes (IL2, IL3, IL4) have been implicated for schizophrenia
[23,24]. Moreover, we found 3 retinoic X receptor (RXR) related
signaling pathways: LXR (liver X receptor)/RXR activation, FXR
(farnesoid X receptor)/RXR activation, and PPAR (peroxisome
proliferators-activated receptor) signaling. RXR acts as a master
regulator during ligand-induced transcription activities [25].
Retinoic acid (RA), a metabolic product of retinol, is involved in
the development, regeneration and maintenance of the nervous
system [21]. The disruption of retinoid has been implicated in the
development of schizophrenia [26]. In summary, these enriched
pathways suggest that autoimmune and metabolic systems, which
may interact with environmental factors, have important roles in
the etiology of schizophrenia.
Crosstalk among SZ-enriched pathways. Besides
searching schizophrenia specific pathways, we took a further step
by exploring the interactions and crosstalk between pathways
involving in schizophrenia. This analysis assumes that two
pathways are likely crosstalk if significantly more proteins or
protein interactions are detected between two pathways than
expected by chance [27]. There were a total of 276 pathway pairs
(links) from the 24 enrich pathways. We found 69 were statistically
significantly linked (P#0.01) based on the statistical test described
in Materials and Methods.
Figure 3 shows the crosstalk of these significantly linked
pathways. Two clusters were roughly identified based on the level
of interactions between the pathways. One cluster consisted of 9
pathways including 6 neurodevelopment and 3 common signaling
pathways, as shown in the left part in Figure 3. The second cluster,
as shown in the right part of Figure 3, had 15 pathways, including
1 common signaling pathway, 3 neuronal signaling pathways, 8
immune system-related pathways and 3 RXR-related pathways.
The crosstalk among these 15 pathways was much stronger than
that in the first cluster. These two clusters were connected by three
links. One link, which was between synaptic long-term depression
and Fc epsilon RI signaling, appears interesting because it
connects the immune-related system to brain development.
Schizophrenia molecular network (SMN)
To have an overview of the protein-protein interactions and
molecular regulations, we constructed a schizophrenia molecular
Figure 3. Crosstalk among SZ-enriched pathways. Nodes represent pathways and edges represent crosstalk between pathways. Node area
corresponds to its score, which is 210 logarithm of Fisher’s exact test P value. Red nodes: neurodevelopmental pathways; blue nodes: common
signaling pathways; green nodes: immune-related pathways; and grey nodes: RXR (retinoic X receptor) related pathways.
doi:10.1371/journal.pone.0011351.g003
Schizophrenia Network/Pathways
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network (SMN). We integrated SZ-enriched pathways with the
SZ-specific network, and also enhanced the interactions/regula-
tions by literature surveys. Figure 4 displays the SMN, which
includes four neurotransmitters and their transmembrane recep-
tors (neurotransmitter pathways) and their downstream interac-
tions such as activations, inhibitions, and feedback regulations in
the cellular system. It also includes many common cellular
processes, such as calcium signaling, G-protein coupled receptor
signaling, cAMP-mediated signaling, and MAPK signaling
pathways. The network also describes the secretion process of
small molecules like dopamine; the balance of several effectors, like
the inhibition and excitation effects of GABA and glutamate; and
the cooperation of regulation via feedback loops after the outer-
membrane signal had been transmitted through the membrane
into the cellular system.
This network has many feedback loops linking many biological
processes. Among those loops, the one from N-methyl-D-aspartate
subtype glutamate receptor (NMDAR) to a-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid subtype glutamate receptor
(AMPAR) appeared to be the shortest. The NMDAR-AMPAR
signaling cascade has an important role in apoptosis [28].
Moreover, we observed that those pathways were interlinked via
PKC and AKT, suggesting their important roles in the molecular
mechanisms of schizophrenia. Both PKC and AKT are protein
kinases that are essential in many pathways controlling cell growth
and apoptosis. A recent study found a direct link between PKC
and AKT [29], which enhanced the crosstalk of the pathways in
this molecular network. Overall, this investigation revealed that
schizophrenia is a dynamic process caused by dysregulation of
multiple pathways that are in crosstalk.
Application: identification of novel schizophrenia
candidate genes
To demonstrate that gene network/pathway analysis is useful in
complex diseases, we applied two strategies to select novel
candidate genes based on our network/pathway analysis and
then performed some experimental verifications.
The first strategy was based on schizophrenia subnetwork
analysis. Our SZ-specific network had 233 genes including 135
SZGenes and 98 new genes (non-SZGenes). For each gene in this
network, we identified its smallest P value using the CATIE [30]
and GAIN [31] GWAS markers that mapped to these genes and
Figure 4. Schizophrenia molecular network (SMN). This network was constructed by using schizophrenia related pathways, protein-protein
interactions and literature survey. SZGenes are in red text and neurotransmitters in pink background. The enriched pathways are highlighted in the
boxes with a blue and pink background. Several feedback loops are identified including those highlighted with red lines.
doi:10.1371/journal.pone.0011351.g004
Schizophrenia Network/Pathways
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11351
used the P value to represent its significance signal. CATIE and
GAIN were the only two publicly available GWAS datasets for
schizophrenia when we conducted this study. Mapping SNPs,
identification of the smallest P value of each gene, and limitation of
this approach was described in our previous study [11]. There
were 16,892 genes that appeared in both the CATIE and GAIN
studies. Among them, 1,745 had the smallest P values ,0.05 in
both the studies. Among the 233 genes in the SZ-specific network,
we found 47 whose P values were ,0.05 in both of the CATIE
and GAIN studies. We next tested whether this observation was by
chance. We first randomly selected 1,000 sets of 233 genes from
the 16,892 common genes. For each random set, we counted the
number of genes having P values ,0.05 in both the CATIE and
GAIN datasets (n). For these 1,000 sets, we counted the number of
sets whose n is not less than 47 (m). Then, we calculated empirical
P values by m/1,000. We repeated this randomization 10 times to
estimate the confidence of this approach. We obtained an
empirical P= 0, that is, we could not find any random gene set
having .47 genes whose P values ,0.05, as observed in our SZ-
specific network. This evaluation suggests that genes in our SZ-
network are likely significantly more enriched with small P values
compared to the overall genome. However, caution should be used
in this comparison because this analysis has a bias towards gene
length. The SZGenes are overall longer than other human genes,
thus, they might have more chance to have small P values,
assuming GWAS markers were distributed approximately evenly
in the human genome.
The evaluation done by using independent GWAS markers
indicates that our network analysis may identify a set of new genes
with an enriched association signal. Among the 47 genes whose P
values were ,0.05 in both the CATIE and GAIN datasets, 16
were non-SZGenes. We considered these 16 genes as potential
candidate genes (Table S5). Most of these genes had not been
reported in schizophrenia association studies when we started to
collect SZGenes. Next, we extracted 5 subnetworks based on the
direct interaction of the 16 non-SZGenes with the nodes encoded
by SZGenes and their GWAS P values (Figure S4A). This
procedure resulted in six potential novel candidate genes (DLG2,
EGFR, ESR1, GRIK2, PRKCB1 and ZBTB16). Among them, two
genes (EGFR and ESR1) were included for genotyping in our
independent project involving 180 genes and other four genes not.
Both had markers with P,0.05 (unpublished data). Among the 66
SNPs genotyped in EGFR, six had P,0.05 and the smallest P value
was 0.003481. Among the 37 SNPs genotyped in ESR1, three had
P,0.05 and the smallest P value was 0.001637. Although no
marker passed stringent Bonferroni multiple testing and further
analysis (e.g., haplotype based analysis) and replication is needed,
this preliminary data suggests that our candidate gene selection
approach might be effective. Interestingly, for ESR1, we did not
find any association study reported for schizophrenia when we
collected and analyzed data, but we found a recent positive
association study [32] during our manuscript preparation. This
study further supports our approach.
The second strategy was based on pathway analysis with a
combination of network information. Among the 24 SZ-enriched
pathways, glutamate receptor signaling pathway ranked at the top.
We extracted the glutamate receptor signaling subnetwork from
the human interactome using the Steiner minimal tree algorithm.
This subnetwork included 18 genes (Figure S4B), 12 of which were
among the 160 SZGenes while the other 6 (DLG2, FLNA, GRB2,
GRIK2, HSPA5 and JUB) were non-SZGenes. Among them,
GRIK2 has been reported to have positive association with
schizophrenia while others have not. GRB2 locates in the center
of the subnetwork, which indicates that it might play an important
role in the pathway. Among the four well-known neurotransmitter
pathways (glutamate receptor signaling, GABA receptor signaling,
serotonin receptor signaling and dopamine receptor signaling),
GRB2 appeared in all the four pathways and HSPA5 in three
pathways, and the interaction between GRB2 and HSPA5
appeared in three pathways. Considering the gene length,
functions and chromosome location, we finally selected two genes
(GRB2 and HSPA5, both of which are not long) for follow-up
experimental verification. Using the Haploview program, we
tested the association of seven tagSNPs in gene GRB2 and two
tagSNPs in gene HSPA5 in our Irish Case-Control Study of
Schizophrenia (ICCSS) sample (1,021 cases and 626 controls)
[33]. Interestingly, for GRB2, five SNPs had P,0.05 and the other
two SNPs whose P values were close to 0.05 (unpublished data).
The two smallest P values (0.000253 and 0.00313) were significant
even after Bonferroni correction. We did not observe any
significant signals for the two markers in HSPA5. Although more
samples and markers are needed for verification, these preliminary
results suggest that our network and pathway-based approach for
candidate gene selection might be promising.
Discussion
For complex diseases such as schizophrenia, uncovering
susceptibility genes is a challenging but important task. Traditional
linkage and association studies have been the primary approaches
for this challenge during the last 15 years. Although many loci and
genes have been suggested to be linked to schizophrenia, a low
replication rate and a lack of functional variants to the risk to
schizophrenia have greatly weakened our confidence in the
common disease/common variant hypothesis. Furthermore,
GWA studies for schizophrenia and other psychiatric disorders
have not been as successful as in other diseases or traits such as
cancer, body mass, and height [3,30]. In this study, we
hypothesized that the risk for schizophrenia may accumulate
among schizophrenia genes that interact through their proteins or
in their biological pathways and explored this hypothesis using a
systems biology approach. However, this analysis is still prelim-
inary as no genes have been confirmed to be casual in
schizophrenia, many genes in the SZGene list may be false
positives, and the human interactome and pathway databases are
neither complete nor error- or bias-free.
Both schizophrenia and cancer are complex diseases. Our
examination of schizophrenia and cancer specific networks
revealed major differences, suggesting different effects of genes in
causing these two types of diseases. Cancer genes interact more
strongly with each other and are more likely to cluster in the
network than schizophrenia genes. This feature might be an
artifact of data bias: (1) cancer genes might have been studied
more by investigators regarding fighting cancers; and (2) although
our evaluation suggested SZGenes may be useful, there are likely
more false positives in SZGenes than cancer genes and these false
positives tend to be non-disease genes [11]. To address the first
bias, we examined the properties of the homologous genes in yeast.
We downloaded the yeast PPI data from BioGRID [34]. The yeast
interaction data is not biased towards cancer or schizophrenia.
The same conclusion could be drawn using yeast data. For
example, we found a stronger PPI network for cancer homologous
genes in yeast. It is worth noting that some genes are associated
with both schizophrenia and cancer. It would be interesting to
further investigate whether their roles are different in the
biological networks/pathways to the diseases.
Despite these limitations, this study provides the first compre-
hensive view of the network and pathway characteristics of
Schizophrenia Network/Pathways
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schizophrenia candidate genes. These characteristics demonstrate
that schizophrenia is a complex disorder that involves many genes
and their interactions. Each of these genes may contribute a small
effect to the pathology of schizophrenia. We propose that combing
markers/genes at the network or pathway level has greater power
to detect an association with schizophrenia than the traditional
methods. In this scenario, each mutation might have a different
degree of risk effect. Thus, prior information about the mutations
in some genes in a network/pathway is helpful for detecting signals
in other genes in the same network/pathway. This signal detection
is helpful for biomarker discovery and the design of molecular
diagnosis. Our preliminary experimental work suggests that this
approach is promising.
One recent GWA study indicates that schizophrenia shares
substantial polygenetic component with bipolar disorder, another
mental disorder [3]. One review of genetic vulnerability to different
substances implicates several regions and genes in addiction are also
associated with various substances such as alcohol dependence,
nicotine, cocaine, opioids, and heroin [35]. The review listed 62
addiction genes [35]. For these genes, we found similar network
properties (e.g., a moderate connectivity and intermediate shortest-
path distance) and some common neurodevelopment-related
pathways that were observed for SZGenes. Overall, the accumu-
lating data and information implicates common genetic compo-
nents and their interactions in neuropsychiatric disorders.
Materials and Methods
Global network properties and significance
In a protein-protein interaction (PPI) network, a node represents
a protein and an edge represents an interaction between two nodes.
For node i in the whole human protein-protein interaction network,
we applied two network topological measures to assess the network
characteristics of each gene set: (1) degree, the number of links of
node i in the network [12] and (2) shortest-path length, the number
of links of the shortest path traveling from node i to another node.
The average shortest-path length measures overall navigability of a
network. We extended the measurement of shortest-path length in
two ways: (1) characteristic shortest-path distance, which was the
shortest-path distance from a gene to another gene in the whole
network, and (2) global centrality, which was the shortest-path
length between two proteins both belonging to the same gene list,
allowing transitions through proteins in other categories.
To test the significance of the network properties of a gene set,
we developed an empirical re-sampling approach. For each gene
set of interest having n genes, we randomly selected n genes from
all available proteins (i.e., random gene set) and calculated their
average degree and characteristic shortest-path distance. We
repeated this re-sampling 1,000 times. To estimate the significance
of average degree observed in the gene set of interest, we counted
the number (Ni) of random gene sets whose average degree was
higher than the observed average degree and then calculated an
empirical P value =Ni/1,000. Similarly, for shortest-path distance,
we counted the number (Mi) of random gene sets whose average
shortest-path distance is smaller than the observed distance and
then calculated an empirical P value =Mi/1,000.
Construction of SZ-specific network
To extract a network for SZGenes, we first reconstructed a PPI
network (the human interactome, Text S1). Among the 160
SZGenes, 137 were mapped into the human interactome. We
extracted the subnetwork as a SZ-specific network from the whole
human interactome by using Steiner minimal tree algorithm [15].
In this algorithm, the subnetwork starts with an interesting protein
set and expands step-by-step until all interesting proteins are
netted. Then, the network is simplified to a minimum net
containing SZGenes by shortest-path lengths among interest
proteins. To test the non-randomness of the subnetwork, we first
generated 1,000 random networks with the same number of nodes
and links in the SZ-specific network. We applied the Erdos-Renyi
model in the R igraph package to the randomization process.
Then we estimated the significance of non-randomness by
examining network measures such as average degree, average
shortest-path distance and clustering coefficient. The empirical P
values were calculated similarly as in the subsection above. For
comparison, we obtained a cancer-specific network and estimated
the significance of its non-randomness by running 1,000 random
networks, like we did for the SZ-specific network.
SZ-enriched pathways and their crosstalk
We searched the pathways of 160 SZGenes in the Ingenuity
System (http://www.ingenuity.com) and found 101 canonical
pathways. We further applied the following two criteria to identify
SZ-enriched pathways: 1) the score, which is -10 logarithm of
Fisher’s exact test P value, in a pathway is.2; and 2) the number of
SZGenes involved in a pathway is .5. For pathway crosstalk, we
considered both common proteins (nodes) and common interactions
(edges) between any two pathways. For any pair of SZ-enriched
pathways, we calculated a 262 contingency table, which includes
four counts: n, N-n, r, R-r where n is the number of common nodes
(or links) between two tested pathways in the pair; N is the number
of total nodes (or links) of the two tested pathways, r is the average
number of common nodes (or links) between all possible pairs of SZ-
enriched pathways and R is the average number of proteins (or links)
of all possible pairs of SZ-enriched pathways. For nodes (or links),
we used Fisher’s exact test to calculate P values and adjusted them
by false discovery rate (FDR) using Benjamini-Hochberg procedure
[36]. Therefore, for each pair of the pathways, we calculated two P
values (Pnodes and Plinks). We choose the smaller P value as the criteria
of pathway crosstalk. If the smaller P value is less than 0.01, we
regarded the two pathways significantly have crosstalk.
Supporting Information
Text S1 Detailed Materials and Methods. In this Supporting
Information Text S1, we include additional technical information.
Found at: doi:10.1371/journal.pone.0011351.s001 (0.06 MB
DOC)
Table S1 GO terms significantly enriched in SZGenes (schizo-
phrenia genes) compared to NDEGenes (non-disease non-essential
genes).
Found at: doi:10.1371/journal.pone.0011351.s002 (0.10 MB
DOC)
Table S2 Comparison of genes distributed in SZ-specific
network with those in cancer-specific network.
Found at: doi:10.1371/journal.pone.0011351.s003 (0.04 MB
DOC)
Table S3 Comparison of the number of nodes forming clusters
by different K-cliques in schizophrenia and cancer gene
subnetworks.
Found at: doi:10.1371/journal.pone.0011351.s004 (0.03 MB
DOC)
Table S4 Pathways significantly enriched for schizophrenia
candidate genes.
Found at: doi:10.1371/journal.pone.0011351.s005 (0.05 MB
DOC)
Schizophrenia Network/Pathways
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11351
Table S5 Information of 16 genes in association studies and
GWA studies.
Found at: doi:10.1371/journal.pone.0011351.s006 (0.05 MB
DOC)
Figure S1 Degree distribution of five gene sets. Y-axis represents
the proportion of proteins having a specific degree.
Found at: doi:10.1371/journal.pone.0011351.s007 (0.31 MB TIF)
Figure S2 Shortest-path distance of five gene sets. (A) Charac-
teristic shortest-path distance distribution. Y-axis is the proportion
of proteins having a specific characteristic shortest-path distance.
The average characteristic shortest-path distance and its empirical
P value for randomness from the human interactome are shown in
the table inside. (B) Global centrality distribution. Y-axis is the
proportion of proteins having a specific global centrality. Vertical
line represents the average global centrality of each gene set, which
is also summarized in the inside of the figure.
Found at: doi:10.1371/journal.pone.0011351.s008 (0.92 MB TIF)
Figure S3 Cancer-specific network. Cancer genes are labeled in
red and non-cancer genes in blue. Node area corresponds to its
degree in the human interactome. Node shape indicates its cellular
location: ellipse for cytoplasm, diamond for extracellular space,
triangle for nucleus, square for plasma membrane, and hexagon
for unknown location.
Found at: doi:10.1371/journal.pone.0011351.s009 (0.67 MB TIF)
Figure S4 Selection of novel schizophrenia candidate genes.
Nodes in red denote SZGenes and nodes in grey and green denote
non-SZGenes. (A) Direct interactors of five potential schizophre-
nia candidate genes (in green), which are non-SZGenes but had P
values ,0.05 in both GAIN and CATIE GWA studies. In these
subnetworks, the nodes whose genes having P value ,0.05 in
GAIN are labeled in red asterisk and having P value ,0.05 in
CATIE are labeled in blue asterisk. (B) An extracted glutamate
receptor signaling subnetwork.
Found at: doi:10.1371/journal.pone.0011351.s010 (0.35 MB TIF)
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